The identified research employed a variety of methods to detect alterations in lung cancer epigenetics: 16 studies conducted assays of specific candidate genes as shown in Table 4, which included F2RL3 and AHRR (35–38), CDKN2A, DLEC1, CDH1, DAPK, RUNX3, APC, WIF1, and MGMT (39), SATα, NBL2, and D4Z4 (40, 41), DNMT1, DNMT3a, DNMT3b, TET1, TET2, TET3 (42), L3MBTL1, NNAT, PEG10, GNAS Ex1A, MCTS2, SNURF/SNRPN, IGF2R, RB1, and CYP1B1 (43), CYP1A1 (44), miRNA (45–50). This evidence concerns the gene CDKN2A and lung carcinoma.